Oxana Beskrovnaya Sells 2,339 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,339 shares of the company’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the sale, the insider now directly owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dyne Therapeutics Trading Up 0.5 %

DYN stock opened at $36.59 on Friday. Dyne Therapeutics, Inc. has a one year low of $6.40 and a one year high of $47.45. The firm has a 50-day moving average of $41.07 and a two-hundred day moving average of $33.55. The firm has a market capitalization of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DYN shares. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. JPMorgan Chase & Co. boosted their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Morgan Stanley raised their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Piper Sandler boosted their target price on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new position in Dyne Therapeutics in the 4th quarter worth about $304,000. Rafferty Asset Management LLC grew its stake in shares of Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after buying an additional 24,632 shares in the last quarter. Commodore Capital LP acquired a new position in Dyne Therapeutics in the fourth quarter worth approximately $11,970,000. Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics during the fourth quarter valued at approximately $15,758,000. Finally, Octagon Capital Advisors LP lifted its stake in Dyne Therapeutics by 14.4% in the fourth quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock valued at $10,546,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.